Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT05935553

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence (BABET)

Sponsor: Hospices Civils de Lyon

Interventions Baclofen 30 mg Baclofen 60 mg Placebo

Updated 6 times since 2023 Last updated: Jan 28, 2026 Started: Jan 15, 2026 Primary completion: Oct 30, 2028 Completion: Oct 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05935553, this PHASE2/PHASE3 trial focuses on Benzodiazepine Dependence and remains actively recruiting participants. Sponsored by Hospices Civils de Lyon, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2/PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2/PHASE3
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Nov 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Aug 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospices Civils de Lyon

Data source: Hospices Civils de Lyon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bron, France
• Lyon, France